Amy Sze-Man Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Amy Sze-Man Li has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
Xiao-Qi Wang
Consun Chinese Medicines Research Centre for Renal Diseases, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong SAR, China; Research and Development Centre for Natural Health Products, HKBU Shenzhen Research Institute and Continuing Education, Shenzhen, China
4 shared publications- Xiu-Qiong Fu
Consun Chinese Medicines Research Centre for Renal Diseases, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, China
4 shared publications - Zhi-Ling Yu
School of Chinese Medicine, Hong Kong Baptist University, Hong Kong SAR, China
4 shared publications Jia-Ying Wu
Consun Chinese Medicines Research Centre for Renal Diseases, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong SAR, China; Research and Development Centre for Natural Health Products, HKBU Shenzhen Research Institute and Continuing Education, Shenzhen, China
3 shared publicationsLi Wang
Consun Chinese Medicines Research Centre for Renal Diseases, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong SAR, China; Research and Development Centre for Natural Health Products, HKBU Shenzhen Research Institute and Continuing Education, Shenzhen, China
3 shared publicationsJing-Xuan Bai
Consun Chinese Medicines Research Centre for Renal Diseases, School of Chinese Medicine, Hong Kong Baptist University, Kowloon Tong, Hong Kong
2 shared publications
Latest Publications
- Open Access
- 9 October 2026
- Published by Science Publishing Group in World Journal of Public Health
- Vol. 11 (4) , 392-403
Efficacy and Safety of eLAX TM Probiotic-Botanical Supplement in Improving Constipation: A Single-Center, Single-Arm Study
Background: Functional constipation impairs gut health and quality of life. Okra (Abelmoschus esculentus), traditionally used for treating gastrointestinal complaints, is rich in soluble dietary fiber and mucilaginous polysaccharides thought to increase stool water retention, soften feces, and promote luminal bulk, thereby facilitating colonic transit. Preclinical studies link okra mucilage to gut barrier support and favorable shifts in gut microbiota composition. The eLAX TM Probiotic-Botanical Supplement (eLAX) combines okra extract with Lactobacillus casei probiotics. We evaluated its efficacy and safety in a single-center, open-label, self-controlled study and report the complete 12-week dataset. Methods: Fifty-one adults meeting Rome IV criteria for functional constipation were enrolled at Xiangya Hospital; 49 completed the study and were analyzed. Participants received descending doses of eLAX over 10 weeks with intervening washouts (Weeks 1-2: 4 tablets/day; Week 3 washout; Weeks 4-6: 3/day; Week 7 washout; Weeks 8-10: 2/day), then 2 weeks of observation without product. The primary endpoint was the responder rate (increase in spontaneous bowel movements [SBMs] per 24 h versus baseline) at Weeks 2, 6, 10, and 12. Exploratory endpoints included gut microbiota, PAC-SYM, PAC-QOL-12, bowel diaries (frequency, straining, Bristol Stool Scale [BSS], abdominal pain), and assisted-defecation use. Safety included laboratory tests and colonoscopy in a subset. Results: Responder rates (N=49) were 87.8%, 61.2%, 55.1%, and 42.9% at Weeks 2, 6, 10, and 12. Mean SBM frequency rose from 0.51/day at baseline to 1.88, 1.35, and 1.12/day at Weeks 2, 6, and 10 (all p p =0.0086). Mean time to first bowel movement was 5.88±4.12 h (61.2% within half a day). BSS shifted from types 1-2 toward types 3-7 after 10 weeks (mean +2 grades); 69.3% retained ideal types 3-4 at Week 12. Straining resolved by Week 10; incomplete evacuation and abdominal pain declined. PAC-SYM (0-30) fell from 15.96±3.33 to 1.00±1.98 at Week 10 (−93.73%, p p p =0.0091) and the Bacteroidetes/Firmicutes ratio rose 162.57% ( p <0.0001) at Week 10. No product-related adverse events occurred; colonoscopy (n=10) showed no melanosis coli. Conclusion: Over 12 weeks, eLAX was associated with significant improvements in bowel frequency, stool consistency, symptoms, quality of life, and gut microbiota, with a favorable safety profile. Benefits were most durable in participants without baseline spontaneous defecation; milder cases may need longer low-dose maintenance after tapering.
- 9 October 2026
- Published by Science Publishing Group in World Journal of Public Health
- Vol. 11 (4) , 392-403
Open AccessEfficacy and Safety of eLAX TM Probiotic-Botanical Supplement in Improving Constipation: A Single-Center, Single-Arm Study
Background: Functional constipation impairs gut health and quality of life. Okra (Abelmoschus esculentus), traditionally used for treating gastrointestinal complaints, is rich in soluble dietary fiber and mucilaginous polysaccharides thought to increase stool water retention, soften feces, and promote luminal bulk, thereby facilitating colonic transit. Preclinical studies link okra mucilage to gut barrier support and favorable shifts in gut microbiota composition. The eLAX TM Probiotic-Botanical Supplement (eLAX) combines okra extract with Lactobacillus casei probiotics. We evaluated its efficacy and safety in a single-center, open-label, self-controlled study and report the complete 12-week dataset. Methods: Fifty-one adults meeting Rome IV criteria for functional constipation were enrolled at Xiangya Hospital; 49 completed the study and were analyzed. Participants received descending doses of eLAX over 10 weeks with intervening washouts (Weeks 1-2: 4 tablets/day; Week 3 washout; Weeks 4-6: 3/day; Week 7 washout; Weeks 8-10: 2/day), then 2 weeks of observation without product. The primary endpoint was the responder rate (increase in spontaneous bowel movements [SBMs] per 24 h versus baseline) at Weeks 2, 6, 10, and 12. Exploratory endpoints included gut microbiota, PAC-SYM, PAC-QOL-12, bowel diaries (frequency, straining, Bristol Stool Scale [BSS], abdominal pain), and assisted-defecation use. Safety included laboratory tests and colonoscopy in a subset. Results: Responder rates (N=49) were 87.8%, 61.2%, 55.1%, and 42.9% at Weeks 2, 6, 10, and 12. Mean SBM frequency rose from 0.51/day at baseline to 1.88, 1.35, and 1.12/day at Weeks 2, 6, and 10 (all p p =0.0086). Mean time to first bowel movement was 5.88±4.12 h (61.2% within half a day). BSS shifted from types 1-2 toward types 3-7 after 10 weeks (mean +2 grades); 69.3% retained ideal types 3-4 at Week 12. Straining resolved by Week 10; incomplete evacuation and abdominal pain declined. PAC-SYM (0-30) fell from 15.96±3.33 to 1.00±1.98 at Week 10 (−93.73%, p p p =0.0091) and the Bacteroidetes/Firmicutes ratio rose 162.57% ( p <0.0001) at Week 10. No product-related adverse events occurred; colonoscopy (n=10) showed no melanosis coli. Conclusion: Over 12 weeks, eLAX was associated with significant improvements in bowel frequency, stool consistency, symptoms, quality of life, and gut microbiota, with a favorable safety profile. Benefits were most durable in participants without baseline spontaneous defecation; milder cases may need longer low-dose maintenance after tapering.
- Open Access
- 9 August 2025
- Published by Elsevier in Phytomedicine
- Vol. 146, 157151
Parthenolide inhibits Hsp90α ATPase activity and overcomes acquired BRAF-inhibitor resistance in cutaneous melanoma
- 9 August 2025
- Published by Elsevier in Phytomedicine
- Vol. 146, 157151
Open AccessParthenolide inhibits Hsp90α ATPase activity and overcomes acquired BRAF-inhibitor resistance in cutaneous melanoma
- Open Access
- 8 May 2025
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 187, 118136
Inhibition of the PI3K/AKT signaling pathway contributes to the anti-renal cell carcinoma effects of deoxyelephantopin
- 8 May 2025
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 187, 118136
Open AccessInhibition of the PI3K/AKT signaling pathway contributes to the anti-renal cell carcinoma effects of deoxyelephantopin
- Open Access
- 8 April 2025
- Published by Elsevier in Phytomedicine
- Vol. 141, 156737
A tri-compound formula comprising Ginsenoside Rg1, tetrandrine and icariin alleviates atopic dermatitis symptoms in a mouse model
- 8 April 2025
- Published by Elsevier in Phytomedicine
- Vol. 141, 156737
Open AccessA tri-compound formula comprising Ginsenoside Rg1, tetrandrine and icariin alleviates atopic dermatitis symptoms in a mouse model
- Open Access
- 14 July 2021
- Published by Elsevier in Journal of Ginseng Research
- Vol. 46 (3) , 418-425
Ginsenoside Rg3 in combination with artesunate overcomes sorafenib resistance in hepatoma cell and mouse models
- 14 July 2021
- Published by Elsevier in Journal of Ginseng Research
- Vol. 46 (3) , 418-425
Open AccessGinsenoside Rg3 in combination with artesunate overcomes sorafenib resistance in hepatoma cell and mouse models